newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance

  • Ended Q3 2026 with $24.1 million in cash & restricted cash, including $10.0 million restricted.
  • Reported Q3 2026 net loss of $6.2 million, up from $2.8 million in Q3 2025 due to a $3.2 million manufacturing charge.
  • Q3 2026 R&D expenses were $4.2 million, driven by API manufacturing costs for a potential Phase 3 trial.
  • Q3 2026 G&A expenses remained flat at $1.3 million compared to the prior year.
  • Entered a settlement with Novartis to resolve $4.9 million in legacy liabilities for a $1.0 million payment.
  • Expects Q4 2026 earnings per share between $0.01 & $0.04, driven by an extraordinary gain from debt extinguishment.
  • Anticipates full year 2026 loss per share between $0.73 & $0.76.
  • Phase 2 ovarian cancer trial enrollment continues under FDA Fast Track designation.
  • VA-funded Phase 2 combination trial for small cell lung cancer is enrolling patients across U.S. VA medical centers.
  • Japan Patent Office granted a patent for the stenoparib DRP companion diagnostic protecting rights until 2039.
  • Secured first revenue-generating contract under its CLIA-certified laboratory services strategy in October 2026.
  • Expanded in-house lab capabilities to include proteomics & cell line research to support external partners.
  • Financial guidance for 2027 is not being provided.
Company
Allarity Therapeutics, Inc.
Keywords
Nasdaq:ALLR, Allarity Therapeutics, Inc.